Stockreport

BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc.  (BRTX) 
NASDAQ:AMEX Investor Relations: biorestorative.com/content/investor-relations
PDF Data showed 50% or more of patients reporting 50% improvement in key pain and function scales  No adverse events related to dose-limiting toxicities associated with hyp [Read more]